RE-GROUP
UNDERSTANDING PTSD, ANXIETY & PEPTIDE RESEARCH
RE-GROUP is an educational resource about brain health, stress responses, and current research involving Semax and Selank.
UNDERSTANDING PTSD & ANXIETY
PTSD and anxiety disorders are complex mental health conditions involving interconnected biological, psychological, and environmental factors.
These conditions can affect how the brain processes stress, regulates emotions, and responds to perceived threats.
BRAIN SIGNALING & STRESS RESPONSE
The brain communicates through complex networks of neurons and chemical messengers that help regulate mood, attention, and the stress response.
Disruptions in these systems may contribute to symptoms of PTSD and anxiety. Research continues to explore how various compounds may influence neurological signaling pathways.
ESTABLISHED CARE & SUPPORT
PTSD and anxiety disorders are best evaluated and managed by qualified healthcare professionals. Evidence-based approaches may include:
Treatment plans should be individualized based on each person's specific needs.
SEMAX
AN EXPERIMENTAL HEPTAPEPTIDE- •Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH).
- •Research has investigated Semax in laboratory and preclinical studies for potential neurological applications.
- •In 2026, the FDA concluded there is insufficient clinical information to characterize the safety of intranasal Semax, no safety data for the proposed subcutaneous route, and no published human pharmacokinetic studies.
- •Semax is not a component of an FDA-approved drug.
SELANK
A SYNTHETIC PEPTIDE- •Selank is a synthetic peptide that has been studied in a limited number of human research studies, including studies in individuals with generalized anxiety disorder.
- •Research has also explored potential effects on neurological signaling and brain connectivity.
- •These studies do not establish Selank as an FDA-approved treatment for PTSD or anxiety in the United States.
- •The FDA identifies Selank acetate among bulk substances with potential immunogenicity and peptide-related impurity concerns, and states that important human safety information is lacking.
WHAT THE EVIDENCE SHOWS
LEVELS OF SCIENTIFIC INQUIRYMuch of the research is from laboratory and animal studies.
A limited number of human studies exist, particularly for Selank, but they are generally small in size and scope.
Preclinical findings can help identify potential mechanisms, but do not establish clinical effectiveness in humans.
High-quality, controlled clinical trials are needed to determine safety, dosing, effectiveness, and long-term risks.
Neither Semax nor Selank is an FDA-approved treatment for PTSD or anxiety.
REGULATORY & SAFETY CONSIDERATIONS
Semax and Selank are not FDA-approved treatments for PTSD or anxiety in the United States.
The FDA has identified limited or insufficient safety information for these substances, depending on the route of administration.
Compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed.
The regulatory status of investigational peptides can change as new information becomes available.
QUESTIONS TO DISCUSS WITH A HEALTHCARE PROFESSIONAL
- •What is my specific diagnosis or condition?
- •What evidence-based treatment options are available for my situation?
- •What human clinical evidence exists for Semax or Selank?
- •Are these substances FDA-approved for my condition?
- •What are the known and unknown risks?
- •Could they interact with my current medications or health conditions?
- •How would my symptoms and progress be monitored?
- •What role should therapy, lifestyle changes and support systems have in my care?
LEARN MORE
Reliable, up-to-date information is available from:
Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
fda.gov/drugs/human-drug-compoundingSearch for scientific studies on Semax and Selank
pubmed.ncbi.nlm.nih.gov/18454096/Information on PTSD and anxiety disorders
nimh.nih.gov/health/topics/post-traumatic-stress-disorder-ptsdRE-GROUP: Understanding PTSD, Anxiety & Peptide Research
RE-GROUP is an educational resource about post-traumatic stress disorder (PTSD), anxiety, stress responses, brain signaling, and current research involving Semax and Selank.
PTSD and anxiety disorders are complex mental-health conditions influenced by interactions among neurological, psychological, biological, environmental, and social factors.
Research continues to investigate the brain systems involved in fear, stress, mood, memory, and emotional regulation. Scientists have also investigated peptides and other compounds that may influence neurological signaling.
Research into a neurological pathway or experimental substance should not be interpreted as evidence that the substance is an established treatment for PTSD or anxiety.
PTSD can develop after experiencing or witnessing a traumatic event. Symptoms can involve intrusive memories, avoidance, changes in mood and thinking, heightened alertness, sleep disturbances, and changes in emotional responses.
Anxiety disorders can involve persistent or excessive fear, worry, physical symptoms, avoidance behaviors, and other changes that interfere with daily life.
Although PTSD and anxiety can share certain symptoms, they are not the same condition.
Appropriate evaluation by a qualified healthcare or mental-health professional is important when symptoms are persistent, severe, or interfere with everyday functioning.
The brain processes stress through interconnected neurological systems. Areas involved can include the:
These systems participate in emotional regulation, memory, attention, threat detection, and physiological responses to stress. Research into PTSD and anxiety continues to investigate how changes in these networks may contribute to symptoms.
Understanding these mechanisms can help guide research, but identifying a biological pathway does not establish that modifying that pathway with an experimental peptide will safely or effectively treat a mental-health condition.
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH).
It has been investigated experimentally in neurological research, particularly in studies originating outside the United States. Research has examined Semax in areas including neurological injury, cerebral ischemia, neurobiological signaling, and other neurological applications.
FDA's 2026 evaluation of Semax considered proposed uses including cerebral ischemia, migraine, and trigeminal neuralgia.
FDA concluded that available clinical information was insufficient to characterize the safety profile of Semax administered intranasally. FDA also reported that it identified no safety data for the proposed subcutaneous route, no published human pharmacokinetic studies, and no published clinical studies assessing Semax immunogenicity.
Semax is not a component of an FDA-approved drug. Available evidence does not establish Semax as an FDA-approved treatment for PTSD or anxiety.
Selank is a synthetic peptide that has been investigated in neurological and anxiety-related research.
Unlike many experimental peptides, some published human research involving Selank exists. A study involving 62 patients with generalized anxiety disorder and neurasthenia compared Selank with medazepam and evaluated participants using established psychometric measures. The study reported anxiety-related effects, but its size, population, location, and research design should be considered when interpreting the findings.
Other research has investigated possible effects of Selank on neurological signaling and functional brain connectivity.
These studies provide areas for continued investigation but do not establish Selank as an FDA-approved treatment for generalized anxiety disorder, PTSD, or other mental-health conditions in the United States.
FDA currently identifies Selank acetate among bulk substances that may present significant safety risks in compounding. FDA notes potential immunogenicity concerns related to aggregation and peptide-related impurities and states that important human safety information is lacking.
The evidence involving Semax and Selank varies substantially. Research includes:
- Laboratory studies
- Animal models
- Mechanistic research
- Neurological research
- Limited human studies
- Small clinical studies involving specific patient populations
Selank has some published human research involving generalized anxiety disorder. That does not mean the results establish effectiveness for all anxiety disorders or PTSD.
Similarly, neurological research involving Semax should not be interpreted as evidence that Semax treats PTSD, anxiety, or other psychiatric conditions.
High-quality controlled human clinical trials are necessary to establish safety, effectiveness, appropriate dosing, potential interactions, and long-term risks.
PTSD and anxiety disorders are treatable conditions, and established approaches are available. Depending upon the diagnosis and individual patient, care may include:
Treatment should be individualized according to the patient's diagnosis, symptoms, health history, preferences, and professional clinical judgment.
Experimental peptide research should not replace established mental-health evaluation or evidence-based care.
Semax and Selank are not FDA-approved treatments for PTSD or anxiety in the United States.
FDA currently identifies Semax and Selank acetate among bulk substances associated with potential significant safety concerns in the context of compounding.
In July 2026, FDA presented a detailed evaluation of Semax to its Pharmacy Compounding Advisory Committee. FDA concluded that the available information weighed against placing Semax free base and Semax acetate on the 503A Bulks List.
FDA also notes more generally that compounded drugs are not FDA-approved, meaning the agency does not review their safety, effectiveness, or quality before they are marketed.
These distinctions are especially important when evaluating investigational substances proposed for mental-health or neurological purposes.
Patients learning about PTSD, anxiety, and peptide research may wish to ask:
Research into PTSD, anxiety, stress responses, neuroplasticity, neurotransmitters, brain connectivity, and peptide signaling continues to evolve.
Selank has been examined in limited human studies involving anxiety-related disorders, while Semax has primarily been investigated in other neurological research areas.
These different evidence bases should not be combined to imply that a Semax/Selank combination has been clinically demonstrated to treat PTSD or anxiety.
Additional controlled human clinical research would be necessary to establish the safety and effectiveness of investigational peptide applications.
Patients should distinguish among biological mechanisms, experimental research, limited human studies, established mental-health treatments, and FDA-approved medications when evaluating treatment claims.
This page is provided for general educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment.
References to PTSD, anxiety, peptides, neurological pathways, biological mechanisms, laboratory research, animal studies, or areas of clinical investigation are provided for educational purposes and should not be interpreted as a recommendation or endorsement of a particular substance or treatment.
Discussion of Semax, Selank, or another investigational substance does not establish that the substance is safe, effective, FDA-approved, or appropriate for treating PTSD, anxiety, or another mental-health condition.
Individuals experiencing symptoms of PTSD, anxiety, or another mental-health condition should seek evaluation from an appropriately qualified healthcare or mental-health professional.
Treatment decisions should be individualized based on diagnosis, medical and mental-health history, current medications, potential risks, available clinical evidence, and professional clinical judgment.
FDA approval status, compounding policies, clinical evidence, and regulatory requirements may change. Current information should be verified through FDA and recognized medical and mental-health resources.